Editorials

Lessons from the fatal French study BIA-10-2474

BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2727 (Published 18 May 2016) Cite this as: BMJ 2016;353:i2727

This article has a correction. Please see:

  1. Nicholas Moore, professor of clinical pharmacology
  1. University of Bordeaux, F-33076 Bordeaux, France
  1. nicholas.moore{at}u-bordeaux.fr

Do not test in humans drugs that lack an identified therapeutic potential

In January the phase I study of the drug BIA-10-2474 conducted in Rennes, France, left one initially healthy volunteer dead and three with serious neurological damage, some of which may be permanent.1 2

This was a not unusual phase 1 study of a new wannabe drug and included four substudies: single ascending doses, multiple ascending doses, a food interaction study, and some pharmacodynamic testing looking for potential indications. Dose escalation was based on pharmacokinetic data from animal studies and from the previous series in this phase I study.

The study of single ascending doses took place uneventfully up to the maximum dose of 100 mg. The first four series of multiple ascending doses had no problem up to 20 mg for 10 days. Suddenly, on the fifth day of the fifth series (50 mg daily) one participant developed neurological problems and was admitted to hospital. The next day the other participants received their treatment. Three of the four remaining participants had neurological symptoms …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe